Trial Profile
A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 15 Sep 2009 Actual patient number changed from 415 to 413 as reported by ClinicalTrials.gov.
- 26 Feb 2009 Additional locations identified as reported by ClinicalTrials.gov, last updated 26-Feb-09.
- 26 Feb 2009 Actual patient numbers (415) added as reported by ClinicalTrials.gov.